

## Dartford and Gravesham NHS Trust to pilot ResAppDx

- **Initial pilot in respiratory out-patient clinic before expanding into other clinical areas**
- **First pilot of ResAppDx in an NHS trust**
- **Data and learnings from the pilot will be pivotal in expanding opportunities within the NHS and Europe more broadly**

**Brisbane, Australia, 1 April 2022** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has signed a one year agreement with the Dartford and Gravesham National Health Service (NHS) Trust to pilot the use of ResAppDx, ResApp's CE marked acute respiratory diagnostic test that requires only a smartphone, across its four hospitals (Darent Valley, Queen Mary's, Erith & District, and Gravesham Community). It is expected that the pilot will commence in the third quarter of this calendar year.

The Dartford and Gravesham NHS trust provides a comprehensive range of acute services and some community services to over 500,000 people in Kent, United Kingdom. Initial use will be to assess patients who present to the Trust's respiratory outpatient clinic before expanding use into other areas of the hospital and potentially into primary care. The local academic health science network will also be engaged as part of the trial to collaborate, support and gather data to demonstrate the efficacy of ResAppDx and how it enhances clinical and patient workflows.

**Neil Perry, Director of Digital Transformation at Dartford and Gravesham NHS Trust**, said *"We're really excited about the potential of ResAppDx to accelerate the digital transformation of our Trust and how we support our patients and clinicians. Our clinical team is excited about the potential of ResAppDx to accelerate and enhance the diagnosis and management of our respiratory patients. Our initial pilot will be in the Respiratory Outpatient Clinic where we will build experience, learnings, and clinical advocates before expanding into other clinical areas. We see ResAppDx as a true innovation and our team can't wait to see the impact it brings."*

**CEO and Managing Director of ResApp, Dr Tony Keating** added: *"This is an exciting step forward for ResAppDx in Europe, our first pilot with the NHS is an exciting milestone. We look forward to working closely with Neil and his team at Dartford & Gravesham Trust to help fully realise the benefits that ResAppDx can offer to the Trust. While the revenue from the pilot is not material at this time, we will gain significant learnings, data and experience throughout this process which will support our efforts to commercialise ResAppDx with other NHS Trusts and more broadly in Europe."*

Either party may terminate the agreement with 90 days' notice.

###



### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### **About Dartford and Gravesham NHS Trust**

Dartford and Gravesham NHS trust is one of the largest hospital trusts in North Kent, with services at four sites serving a local population of over 500,000 people. During 2020-21, the trust had more than 100,000 emergency attendances, 130,000 virtual outpatient appointments and 28,000 planned admissions across 500 hospital beds. The trust is a founding member of Guys and St Thomas' Healthcare Alliance which enables them to access the expertise, and knowledge of a major London teaching hospital, providing better care and better outcomes for the people of Dartford and Gravesham. For more information, please visit <https://www.dgt.nhs.uk>.

### **Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*